Table 4

Correlation between RT-PCR results and tissue CEA expression in colorectal cancer patients

Patients diagnosed withPatientSite of primary tumorStageSite of metastasisSerum CEA (ng/ml)CEA RT-PCRTissue CEA expressiona (%)
Primary nonmetastatic cancer2RectumA1.4 (−)+++85 (++)
7RectumB13.0 (−)++40 (+++)
8RectumB12.8 (−)++>90 (++)
9RectumB12.7 (−)10 (+)
12RectumB10.9 (−)25 (+)
13Colon & rectumB1b1.7 (−)++70 (+++)
14SigmaB22.3 (−)+++>90 (+++)
17RectumB21.7 (−)+50 (++)
19RectumB21.1 (−)+>90 (+++)
20ColonB20.4 (−)65 (++)
21ColonB20.2 (−)50 (++)
29RectumC20.6 (−)+++50 (+++)
Metastatic disease30ColonDLiver433.5 (+)+10 (+/−)
31ColonDLiver311.6 (+)+++>90 (+++)
32ColonDLiver257.4 (+)+20 (+)
38RectumDLiver10.2 (+)+++85 (++)
39SigmaDPeritoneum8.7 (+)+50 (++)
44ColonDMultiple1.5 (−)Negc
45ColonDLiver1.5 (−)Neg
46SigmaDLiver1.0 (−)++15 (+++)
49RectumRECdLocoregional3.9 (−)+10 (+/−)
  • a CEA tissue expression was evaluated by immunohistochemical analysis as described in “Material and Methods.”

  • b Synchronous adenocarcinomas of the right colon and the rectum.

  • c Neg, CEA was evaluated only on biopsies obtained from liver metastases (taken for diagnostic purposes).

  • d REC, recurrent.